Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17350540 | 0.86 | CA12 (0.47) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2143224 | 0.83 | CA12 (0.42) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL14779262 | 0.83 | GAA (0.46) | GAAALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8345094 | 0.81 | GAA (0.45) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL890842 | 0.81 | GAA (0.45) | GAAALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL32665755 | 0.81 | AGER (0.40) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10430735 | 0.81 | MCHR1 (0.44) | AGERALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8402277 | 0.81 | MCHR1 (0.44) | AGERALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8402280 | 0.81 | MCHR1 (0.44) | AGERALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL872063 | 0.81 | AGER (0.48) | AGERGAAALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884034-A | Process for the manufacture of adalimudine via hydrogenation of an imine | H.隆德贝克有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2349351-A2 | IMAGING AND RADIOTHERAPY METHODS | GE Healthcare Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100292478-A1 | PROCESS OF PREPARING A RADIOACTIVE COMPOUND CONTAINING A FLUORINE-18 ISOTOPE | GACHON UNIVERSITY OF MEDICINE & SCIENCE INDUSTRY- ACADEMIC COOPERATION FOUNDATION (KR) | 2010-11-18 | — | — | US | disclosed |
| WO-2010048144-A2 | IMAGING AND RADIOTHERAPY METHODS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| US-20080279769-A1 | Enzyme Inhibitor Imaging Agents | SOLBAKKEN MAGNE | 2008-11-13 | — | — | US | disclosed |
| EP-1682113-B1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1853324-A1 | CASPASE-3 SUBSTRATE COMPRISING IMAGING AGENTS | GE Healthcare Limited (GB) | 2007-11-14 | — | — | EP | disclosed |
| EP-1763371-A2 | NOVEL IMAGING AGENTS COMPRISING CASPASE-3 INHIBITORS | GE Healthcare Limited (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-20070036258-A1 | Process for producing radioactive fluorine compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2006082434-A1 | CASPASE-3 SUBSTRATE COMPRISING IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2006-08-10 | — | — | WO | disclosed |
| EP-1682113-A1 | INHIBITOR IMAGING AGENTS | GE Healthcare Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| US-20060120956-A1 | Imaging agents comprising barbituric acid derivatives | KOPKA KLAUS | 2006-06-08 | — | — | US | disclosed |
| WO-2006032911-A2 | METALLOPROTEINASE INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
| EP-1549317-A1 | IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES | GE Healthcare Limited (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005053752-A2 | NOVEL IMAGING AGENTS COMPRISING CASPASE-3 INHIBITORS | GE HEALTHCARE LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005049005-A1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004032936-A1 | IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES | AMERSHAM PLC (GB) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | AGER 935/4885GAA 133/4885ALDH1A1 3/4885 |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | AGER 935/4885GAA 133/4885ALDH1A1 3/4885 |
| US-20100292478-A1 | PROCESS OF PREPARING A RADIOACTIVE COMPOUND CONTAINING A FLUORINE-18 ISOTOPE | UHRF1, FTO, AGO2 | AGER 1107/4885GAA 2180/4885ALDH1A1 330/4885 |
| US-20060120956-A1 | Imaging agents comprising barbituric acid derivatives | CA5A, GABRA5, CA5B | AGER 77/4885GAA 2029/4885ALDH1A1 1222/4885 |
| US-20080279769-A1 | Enzyme Inhibitor Imaging Agents | MMP3, MMP1, MMP10 | AGER 1599/4885GAA 140/4885ALDH1A1 536/4885 |
| US-20070036258-A1 | Process for producing radioactive fluorine compound | AFF1, AFF4, RER1 | AGER 2179/4885GAA 1109/4885ALDH1A1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.